Kala Pharmaceuticals, a Waltham, MA-based developer of innovative products that treat a wide range of debilitating diseases by penetrating the mucosal barrier, raised $11.5m in a Series A equity financing.
The round was led by new investor Crown Venture Fund, the vc arm of the Crown family of Chicago, with participation from existing investors Lux Capital Management, Polaris Venture Partners and Third Rock Ventures.
The company intends to use the capital to advance a portfolio of innovative ophthalmic programs based on its Mucosal Penetrating Product (MPP) platform through clinical proof of concept.
Led by Guillaume Pfefer, Ph.D., CEO, Kala Pharmaceuticals is developing products which are capable of penetrating mucosal barriers for the treatment of major diseases that affect the eyes, lungs, gastrointestinal tract, and female reproductive system.
The company was founded by:
– Dr. Justin Hanes of The Johns Hopkins University School of Medicine,
– Dr. Robert Langer of the Massachusetts Institute of Technology, and
– Dr. Colin Gardner formerly of TransForm Pharmaceuticals/Johnson & Johnson and Merck.